专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US10261101B2 Lipidomic biomarkers for identification of high-risk coronary artery disease patients 有权
公开(公告)号：US10261101B2
公开(公告)日：2019-04-16
申请号：US15803252
申请日：2017-11-03
申请人： ZORA BIOSCIENCES OY
发明人： Reijo Laaksonen , Kim Ekroos , Reini Hurme , Riikka Katainen
IPC分类号： G01N33/92
摘要： The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided is an antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.

2. 发明申请

US20170082644A1 BIOMARKERS FOR SENSITIVE DETECTION OF STATIN-INDUCED MUSCLE TOXICITY 审中-公开
公开(公告)号：US20170082644A1
公开(公告)日：2017-03-23
申请号：US15363376
申请日：2016-11-29
申请人： Zora Biosciences OY
发明人： Reijo Laaksonen , Kim Ekroos , Reini Hurme , Riikka Katainen , Minna Janis , Kirill Tarasov
IPC分类号： G01N33/92
CPC分类号： G01N33/92 , G01N2570/00 , G01N2800/10 , G01N2800/2871 , G01N2800/325
摘要： The present invention inter alia provides a method, and uses thereof, of predicting statin-induced muscle toxicity or its complications, such as myalgia, myopathy and rhabdomyolysis, by detecting the lipid concentrations or lipid-lipid concentration ratios of a biological sample and comparing them to a control. This method has identified lipid markers that are more specific and sensitive in detecting these statin-induced muscle toxicity than the currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, statin-induced muscle toxicity. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of statin-induced muscle toxicity.

3. 发明授权

US09459264B2 Lipidomic biomarkers for atherosclerosis and cardiovascular disease 有权
公开(公告)号：US09459264B2
公开(公告)日：2016-10-04
申请号：US14712422
申请日：2015-05-14
申请人： ZORA BIOSCIENCES OY
发明人： Reijo Laaksonen , Kim Ekroos , Reini Hurme , Riika Katainen
IPC分类号： G01N33/92
CPC分类号： G01N33/92 , A61K31/366 , A61K31/397 , G01N2405/04 , G01N2570/00 , G01N2800/32 , G01N2800/323 , G01N2800/324 , G01N2800/325 , G01N2800/50 , G01N2800/52
摘要： The present invention inter alia provides a method, and use thereof, of diagnosing and/or predicting atherosclerosis or CVD by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in detecting and predicting atherosclerosis and CVD than currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating atherosclerosis or CVD. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of atherosclerosis or CVD.

4. 发明申请

US20150362513A1 CERAMIDES AND THEIR USE IN DIAGNOSING CVD 有权
标题翻译：陶瓷及其在诊断CVD中的应用
公开(公告)号：US20150362513A1
公开(公告)日：2015-12-17
申请号：US14677595
申请日：2015-04-02
申请人： ZORA BIOSCIENCES, OY
发明人： Reijo Laaksonen
IPC分类号： G01N33/92
CPC分类号： G01N33/92 , A61K31/164 , C07B59/001 , G01N2405/08 , G01N2458/15 , G01N2800/32 , G01N2800/324 , G01N2800/50 , G01N2800/52
摘要： The present invention inter alia provides a method, and use thereof, of predicting CV complications such as AMI, ACS, stroke, and CV death by determining the concentrations of at least one ceramide of Group A and at least one ceramide of Group B in a biological sample and comparing those concentrations to a control. Finding a decreased concentration of at least one Group A ceramide and an increased concentration of at least one Group B ceramide indicates that the subject has an increased risk of developing one or more CV complications. Also provided are a newly identified subset of ceramide molecules, labelled versions thereof, and kits and compositions comprising the same for use in predicting and/or diagnosing CV complications.
摘要翻译：本发明尤其提供了通过测定A组中至少一种神经酰胺和至少一种B组神经酰胺的浓度来预测CV并发症如AMI，ACS，中风和CV死亡的方法及其用途。生物样品，并将这些浓度与对照组比较。发现降低浓度的至少一种A组神经酰胺和增加浓度的至少一种B组神经酰胺表明受试者具有发展一种或多种CV并发症的风险增加。还提供了新确定的神经酰胺分子的子集，其标记的版本，以及包含其的用于预测和/或诊断CV并发症的试剂盒和组合物。

5. 发明申请

US20190113531A1 CERAMIDES AND THEIR USE IN DIAGNOSING CVD 审中-公开
公开(公告)号：US20190113531A1
公开(公告)日：2019-04-18
申请号：US16218363
申请日：2018-12-12
申请人： ZORA BIOSCIENCES OY
发明人： Reijo Laaksonen
IPC分类号： G01N33/92 , C07B59/00 , A61K31/164
摘要： The present invention inter alia provides a method, and use thereof, of predicting CV complications such as AMI, ACS, stroke, and CV death by determining the concentrations of at least one ceramide of Group A and at least one ceramide of Group B in a biological sample and comparing those concentrations to a control. Finding a decreased concentration of at least one Group A ceramide and an increased concentration of at least one Group B ceramide indicates that the subject has an increased risk of developing one or more CV complications. Also provided are a newly identified subset of ceramide molecules, labelled versions thereof, and kits and compositions comprising the same for use in predicting and/or diagnosing CV complications.

6. 发明授权

US09841431B2 Lipidomic biomarkers for identification of high-risk coronary artery disease patients 有权
公开(公告)号：US09841431B2
公开(公告)日：2017-12-12
申请号：US14875087
申请日：2015-10-05
申请人： ZORA BIOSCIENCES OY
发明人： Reijo Laaksonen , Kim Ekroos , Reini Hurme , Riikka Katainen
IPC分类号： G01N33/92
CPC分类号： G01N33/92 , G01N2405/04 , G01N2405/06 , G01N2570/00 , G01N2800/324 , G01N2800/50 , G01N2800/52
摘要： The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided is an antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.

7. 发明申请

US20170160264A1 USE OF CERAMIDES AND LPLs IN DIAGNOSING CVD 审中-公开
公开(公告)号：US20170160264A1
公开(公告)日：2017-06-08
申请号：US15371661
申请日：2016-12-07
申请人： ZORA BIOSCIENCES, OY
发明人： Marko Sysi-Aho , Mika Hilvo , Kim Ekroos , Reini Hurme , Reijo Laaksonen , Virve Väisänen
IPC分类号： G01N33/49
CPC分类号： G01N33/492 , G01N33/92 , G01N2800/2871 , G01N2800/324 , G01N2800/52
摘要： The present invention inter alia provides a method, and use thereof, of predicting CV events such as AMI, ACS, stroke, and CV death by determining the concentration of at least one ceramide of Formula I or one lysophospholipid of Formula II and/or III and at least one lysophospholipid of Formula IV, V, VI, VII and/or VIII in a biological sample and comparing those concentrations to a control. Finding an increased concentration of the at least one Formula I ceramide or Formula II and/or III lysophospholipid and a decreased concentration of the at least one Formula IV, V, VI, VII and/or VIII lysophospholipid indicates that the subject has an increased risk of developing one or more CV events. The present disclosure also provides a method, and use thereof, of diagnosing subjects suffering acute ischemia. Also provided are kits and compositions comprising the same for use in predicting and/or diagnosing CV events.

8. 发明授权

US09347960B2 Ceramides and their use in diagnosing CVD 有权
标题翻译：神经酰胺及其在诊断CVD中的应用
公开(公告)号：US09347960B2
公开(公告)日：2016-05-24
申请号：US14677595
申请日：2015-04-02
申请人： ZORA BIOSCIENCES, OY
发明人： Reijo Laaksonen
IPC分类号： G01N33/92 , C07B59/00
CPC分类号： G01N33/92 , A61K31/164 , C07B59/001 , G01N2405/08 , G01N2458/15 , G01N2800/32 , G01N2800/324 , G01N2800/50 , G01N2800/52
摘要： The present invention inter alia provides a method, and use thereof, of predicting CV complications such as AMI, ACS, stroke, and CV death by determining the concentrations of at least one ceramide of Group A and at least one ceramide of Group B in a biological sample and comparing those concentrations to a control. Finding a decreased concentration of at least one Group A ceramide and an increased concentration of at least one Group B ceramide indicates that the subject has an increased risk of developing one or more CV complications. Also provided are a newly identified subset of ceramide molecules, labelled versions thereof, and kits and compositions comprising the same for use in predicting and/or diagnosing CV complications.
摘要翻译：本发明尤其提供了通过测定A组中至少一种神经酰胺和至少一种B组神经酰胺的浓度来预测CV并发症如AMI，ACS，中风和CV死亡的方法及其用途。生物样品，并将这些浓度与对照组比较。发现降低浓度的至少一种A组神经酰胺和增加浓度的至少一种B组神经酰胺表明受试者具有发展一种或多种CV并发症的风险增加。还提供了新确定的神经酰胺分子的子集，其标记的版本，以及包含其的用于预测和/或诊断CV并发症的试剂盒和组合物。

9. 发明申请

US20160018423A1 NON-HIGH DENSITY LIPOPROTEIN DERIVED CVD MARKERS 审中-公开
标题翻译：非高密度脂蛋白衍生化CVD标记
公开(公告)号：US20160018423A1
公开(公告)日：2016-01-21
申请号：US14773095
申请日：2014-03-07
申请人： ZORA BIOSCIENCES OY
发明人： Reijo Laaksonen
IPC分类号： G01N33/92
CPC分类号： G01N33/92 , A61K31/00 , A61K38/1709 , G01N2333/775 , G01N2405/02 , G01N2405/04 , G01N2405/08 , G01N2570/00 , G01N2800/32 , G01N2800/323 , G01N2800/324 , G01N2800/50 , G01N2800/52
摘要： The present invention inter alia relates to methods and uses involving the determination of lipid/lipid concentration ratios in order to diagnose, predict, prevent and/or treat atherosclerosis or cardiovascular disease (CVD) and its complications including, e.g., acute myocardial infarction. The methods include analyzing lipid concentrations and resulting lipid/lipid concentration ratios of a non-high density lipoprotein samples from patients and comparing them to a control.
摘要翻译：本发明尤其涉及涉及确定脂质/脂质浓度比以便诊断，预测，预防和/或治疗动脉粥样硬化或心血管疾病（CVD）及其并发症（包括例如急性心肌梗死）的方法和用途。方法包括分析来自患者的非高密度脂蛋白样品的脂质浓度和所得脂质/脂质浓度比，并将其与对照进行比较。

10. 发明申请

US20150260737A1 LIPIDOMIC BIOMARKERS FOR THE PREDICTION OF CARDIOVASCULAR OUTCOMES IN CORONARY ARTERY DISEASE PATIENTS NOT UNDERGOING STATIN TREATMENT 有权
标题翻译：用于预防冠状动脉疾病患者心脏病变的不良生物标志物不能接受治疗
公开(公告)号：US20150260737A1
公开(公告)日：2015-09-17
申请号：US14722964
申请日：2015-05-27
申请人： Zora Biosciences OY
发明人： Reijo Laaksonen , Kim Ekroos , Reini Hurme , Riikka Katainen
IPC分类号： G01N33/92
CPC分类号： G01N33/92 , G01N2570/00 , G01N2800/042 , G01N2800/32 , G01N2800/324 , G01N2800/50 , G01N2800/70
摘要： The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided are antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.
摘要翻译：本发明尤其提供了通过检测生物样品的脂质浓度或脂质比例并将其与对照进行比较来预测严重的CVD并发症如AMI或CVD死亡的方法及其用途，并且鉴定了特异性脂质标记物在预测这些CVD并发症方面比目前使用的临床标志物更具体和灵敏。还提供了针对所述脂质的抗体及其用于预测，诊断，预防和/或治疗CVD并发症的用途。本发明另外涉及包含脂质和/或其抗体的试剂盒，用于CVD并发症的预测和/或诊断。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式